Key Highlights

  • Moderna (NASDAQ:MRNA) fell 7.23% in premarket trading on October 26, 2026 even though Phase 3 results for its personalized melanoma vaccine with Merck showed a recurrence-free survival hazard ratio of 0.58.
  • A hazard ratio of 0.58 means a 42% lower relative risk of recurrence or death than the comparison group, and distant metastasis-free survival had a hazard ratio of 0.62, simple arithmetic.
  • The INTerpath-001 results were presented as a late-breaker at ESMO and published in the New England Journal of Medicine, but the press release was dated October 22, 2026, not October 26.
  • Merck (NYSE:MRK) moved 1.1% lower on October 22, so the reason for Moderna's fall on Monday is not established, and the premarket move may differ from the regular session.

The Data and the Date Conflict

Moderna (NASDAQ:MRNA) and Merck reported Phase 3 results from the INTerpath-001 trial of an individualized neoantigen therapy, a personalized cancer vaccine, in melanoma. The trial showed a recurrence-free survival hazard ratio of 0.58 and a distant metastasis-free survival hazard ratio of 0.62. The company release was dated October 22, 2026, and Merck shares moved 1.1% lower that day, yet the 7.23% fall for Moderna is dated October 26 in published market data. Because the data were already public by then, the Monday decline is not explained by new trial information, and the specific cause was not available for this article. Moderna's partner Merck is a much larger company, so its shares reacted less to the same news.

What the Hazard Ratio Means

A hazard ratio compares the rate of events, here cancer recurrence or death, in the treated group with the rate in the comparison group over time. A ratio of 0.58 means the treated group had about 42% fewer events at any given moment, a relative reduction and not an absolute one. A ratio of 0.62 for distant metastasis-free survival means a 38% lower relative risk of cancer spreading, simple arithmetic. The results were presented as a late-breaker at the European Society for Medical Oncology congress and published in the New England Journal of Medicine. Investors sometimes sell after good data when the result was widely expected, a pattern known as selling the news.

Risks and What to Watch

Regulatory approval of a personalized vaccine requires review of manufacturing, safety and durability of benefit. The data are for melanoma patients after surgery, and results may not apply to other tumor types. Moderna also faces pricing pressure for its respiratory vaccines and heavy research spending. Investors can watch for regulatory filing plans, further trial data, the Federal Reserve decision on October 28, 2026 and healthcare sector flows. Medical conferences concentrate news flow, and investors who bought ahead of the presentation may take profits afterward. A premarket move can reverse in the regular session, so the closing figure matters. Cash burn is another consideration, because late-stage trials are expensive. The partnership with Merck shares cost and reward, which lowers the financial risk for Moderna but also limits its share of any profit. Nothing in this article is investment advice.

Where Things Stand

The answer is that the reason for the 7.23% premarket fall is not established, because the Phase 3 data and the release were dated October 22, 2026, and the shares may be reacting to sector flows, profit-taking or other news. Moderna (NASDAQ:MRNA) reported a hazard ratio of 0.58 with Merck. Regulatory plans and the regular-session reaction are the next catalysts, and a clear filing timetable would give investors a firmer basis than a single day of trading.